Blood Donations and Risk of Coronary Heart Disease in Men

Methods

Results

During 139 176 person-years of follow-up, we documented 459 events, including 328 nonfatal myocardial infarctions and 131 coronary deaths. Differences in coronary risk factors between blood donors and never donors were modest, except for a lower prevalence of diabetes among blood donors (Table 1⇓). We found virtually no association between the number of blood donations and the risk of myocardial infarction (Table 2⇓). The age-adjusted RR for men in the highest category of blood donations (≥30) compared with never donors was 1.2 (95% CI 0.8 to 1.8) and was not materially changed by further adjustment for other coronary risk factors; the analogous RR for fatal CHD was 1.0 (0.5 to 2.2).

Because previous investigations have suggested that high body iron stores may be particularly deleterious in men with high blood cholesterol concentrations or diabetes,¹⁹ we examined the association between blood donation and risk of CHD among men with these risk factors (Table 3⇓). Men with hypercholesterolemia did not appear to benefit from blood donation; the RR for the top category of donors versus never donors was 1.2 (0.6 to 2.4). The small number of donors among men with diabetes did not allow a precise estimate to be made in this subgroup (RR 0.7, 0.1 to 5.4). Finally, Finnish investigators have hypothesized that the lack of association between iron stores and risk of CHD in US studies may be due to the high frequency of the consumption of antioxidant vitamins or aspirin, which may reduce the deleterious effects of iron.²⁰ We therefore examined the association between blood donation and the risk of myocardial infarction in our cohort among men who did not take vitamin E or aspirin on a regular basis; we still found no association (Table 3⇓).

Discussion

The present findings do not support the hypothesis proposed by Sullivan¹ in 1981 that depletion of body iron stores reduces the risk of CHD. This hypothesis was originally formulated to explain the low risk of CHD among premenopausal women, who are iron depleted due to menstrual bleeding, and the observation of an increased risk of CHD among women who had undergone hysterectomy without oophorectomy.^{1 21} Subsequent observations that the risk of CHD in women who receive postmenopausal estrogen replacement therapy is similar to that of premenopausal women²² suggested that reduced estrogen levels rather than excess iron account for the increased risk after menopause. A beneficial effect of long-term replacement therapy may, however, be offset by a temporary increase in risk among women with preexisting CHD.²³ The cardiomyopathy of hemochromatosis was also quoted in support of the hypothesis,¹ although there is no evidence of a positive association between hemochromatosis and coronary artery disease.²⁴ Renewed interest in the possibility that iron is a major risk factor for CHD has followed the 1992 report from Finland of a strong association between serum ferritin levels and the risk of myocardial infarction in men.¹⁹

Iron can catalyze the formation of reactive oxygen species and promote lipid peroxidation in vitro.² In addition, the results of animal experiments indicate that iron overload increases myocardial damage caused by anoxia and reperfusion.^{3 8} This effect may be related to the generation in the ischemic myocardium of superoxide and hydrogen peroxide, which in the presence of free iron are transformed into highly reactive radicals.^{3 5} Furthermore, rabbits experimentally overloaded with iron developed more extensive atherosclerosis when fed high-cholesterol diets.⁴ Although these studies support a potential adverse effect of iron, their relevance to human disease remains to be established. In randomized trials among Finnish men, the in vitro resistance of VLDL and LDL to oxidation was modestly increased with three 500-mL blood donations over a course of 14 weeks²⁵ and decreased with iron sulfate supplementation.²⁶ On the other hand, attempts to relate iron status to the degree of atherosclerosis measured with Doppler sonography in the carotid artery have produced conflicting results.^{27 28 29} Several investigators attempted to directly relate iron status to the occurrence of CHD. A few years ago, we reviewed these epidemiological studies and concluded that evidence of an adverse effect of iron was unconvincing.³⁰ Several new studies have been published since then, including 2 prospective investigations that used serum ferritin as a measure of iron stores.⁷ The use of ferritin is important, because null results obtained in investigations that used serum iron or transferrin saturation may be attributed to their poor correlation with iron stores within the physiological range.³⁰ Overall, the association between serum ferritin and risk of CHD has been examined in 6 separate cohorts.^{7 19 31 32 33 34} A significant positive relation was found in 2: the Kuopio Study in Finland¹⁹ and the Bruneck Study in Italy.³³ This last investigation, however, included individuals with prevalent CHD, which may have contributed to the positive findings.

More recently, 2 groups of investigators examined the risk of CHD among heterozygous carriers of the hemochromatosis gene. One of these investigations was conducted among participants in the Kuopio Study. The RR of acute myocardial infarction among carriers of the hemochromatosis gene (76 heterozygous and 1 homozygous) compared with noncarriers was 2.3 (95% CI 1.1 to 4.8; P=0.03).³⁵ The second investigation was conducted in the Netherlands among 12 239 women 51 to 69 years of age who were followed for 16 to 18 years.³⁶ The RR for fatal myocardial infarction among women who carried the hemochromatosis gene compared with noncarriers was 1.5 (95% CI, 0.9 to 2.5; P=0.14). Although these data are consistent with the hypothesis that iron is a risk factor for CHD,³⁷ there are alternative explanations for these findings. The hemochromatosis gene is in the major histocompatibility complex region of chromosome 6. Several genes in this region are highly polymorphic and encode proteins involved in immune and inflammatory responses. Thus, the reported associations could be due to linkage disequilibrium between the hemochromatosis gene and other polymorphic genes. Most importantly, even if a specific association between the hemochromatosis gene and risk of CHD were to be confirmed, it would still not imply that the increased risk is related to the iron accumulation itself rather than to other metabolic effects. Therefore, a direct assessment of the role of iron stores in the risk of CHD remains necessary.

The comparison of blood donors with nondonors appears to provide a strong test of the iron hypothesis, because of the marked contrast in body iron stores of regular donors compared with those of nondonors.¹⁰ Although it may be expected that blood donors are on average healthier than nondonors, the fact that we found little difference in the major coronary risk factors between the 2 groups in this relatively homogeneous cohort of health professionals and the similarity between age-adjusted and multivariate RRs in our analyses suggest that confounding is modest in these data. Moreover, confounding would be more likely to cause an overestimation than an underestimation of the protective effects of blood donation. Attenuation of any association between blood donation and risk of CHD could have occurred if there was substantial error in the self-reported number of blood donations. However, the 3-fold variation in serum ferritin levels that we found in the validation study between frequent donors and never donors suggests that any such attenuation would have been modest. Finally, the high response rates minimized bias from losses to follow-up. A 6% loss to follow-up is among the lowest in prospective studies, and potential for bias is minimal except under the most unusual circumstances. Thus, the lack of association between a history of blood donation and the risk of CHD in this large cohort provides strong evidence against the hypothesis that iron depletion reduces coronary risk among healthy US men.

The association between blood donation and risk of coronary events was previously examined in 2 investigations: 1 in Nebraska¹¹ and 1 in Kuopio, Finland.¹² In the Nebraska study, blood donors had half the risk of cardiovascular events than nondonors in crude analyses, but this difference was attenuated and no longer significant after adjustment for potential confounders. Moreover, this residual association is likely to have been spurious, because the history of blood donation was obtained retrospectively via telephone at the end of the follow-up, and the fact that the occurrence of a cardiovascular event may have changed the blood donation habits was ignored. On the other hand, in the Kuopio Study, men who donated blood in the 2 years before the baseline had a markedly reduced risk of CHD compared with nondonors during the 8 years of follow-up, and the difference remained significant after adjustment for potential confounders (RR 0.12, 95% CI 0.02 to 0.86).

One of the differences between our study and the Finnish study is that the Kuopio cohort included men with a history of CHD at baseline. Analyses were adjusted for the presence or absence of coronary history that, as expected, was much more common among nondonors but not for the severity of the disease, so some residual confounding is likely. It seems unlikely, however, that this could entirely explain the strong inverse association that was reported. In addition, there are the marked differences between the participants in each study, such as the lower prevalence of smoking, higher use of antioxidant vitamins, and lower mean cholesterol levels in the US health professionals compared with the Finnish men. Differences in cholesterol levels and use of antioxidant vitamins do not appear to explain the discordant results, because we found no association between blood donation and risk of CHD among men with history of high cholesterol or nonusers of vitamin E or multiple vitamins. However, there were too few current smokers or diabetics in our cohort to obtain stable RR estimates within these groups; therefore, we cannot exclude the possibility that they may benefit from blood donation. Also, we cannot exclude the possibility that a frequency of blood donation sufficiently high to cause a substantial reduction in hematocrit could reduce the risk of CHD. A modest but significant association between hematocrit and risk of CHD was shown in a recent meta-analysis of prospective studies.³⁸

In summary, the results of our study suggest that body iron stores are not a major coronary risk factor among US men without previous cardiovascular disease or diabetes. This conclusion is consistent with previous prospective investigations that found no association between serum ferritin and risk of CHD.